Trials / Unknown
UnknownNCT04475224
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
A Non-randomized, Multicenter, Confirmatory Study by Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Kringle Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
This study is non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KP-100IT | Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times |
Timeline
- Start date
- 2020-07-13
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
- First posted
- 2020-07-17
- Last updated
- 2022-08-26
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04475224. Inclusion in this directory is not an endorsement.